Keytruda Bladder Cancer Advisory Cmte. To Discuss Clinical Meaningfulness Of Complete Response Rate

US FDA's questions about Keytruda's increased response rate in Merck's study compared to the historical control were raised in a new point-counterpoint advisory committee briefing document format.

Human Body Organs (Urinary Bladder). 3D
The only other treatment approved in the proposed high-risk bladder cancer indication is not in treatment guidelines due to lack of efficacy. • Source: Shutterstock

US Food and Drug Administration officials wonder whether the 20-point increase in complete response rate shown by Merck & Co. Inc.'s Keytruda in a high-risk bladder cancer is clinically meaningful given the product's safety profile.

Merck has proposed Keytruda (pembrolizumab) for treatment of adults with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers